1Q26: US Ph3 Deni' Acne Trial Start On Track For 2H26; Topline Likely By YE27

Research evidence excerpt

1Q26: US Ph3 Deni' Acne Trial Start On Track For 2H26; Topline Likely By YE27

TD Cowen Sagimet Biosciences

Global Research May 12, 2026

VALUATION METHODOLOGY AND RISKS

Valuation Methodology

Biotechnology:

In calculating our 12-month target price, we employ one or more valuation methodologies,

which include a discounted earnings analysis, discounted cash flow analysis, net present value

analysis and/or a comparable company analysis. These analyses may or may not require

the use of objective measures such as price-to-earnings or price-to-sales multiples as well as

subjective measures such as discount rates.

We make investment recommendations on certain early stage, pre-revenue companies based

upon an assessment of their business model, technology, probability of market success,

and the potential market opportunity, balanced by an assessment of applicable risks. Such

companies may not be assigned a price target.

Investment Risks

There are multiple risks that are inherent with an investment in the biotechnology sector.

Beyond systemic risk, there is also clinical, regulatory, and commercial risk. Additionally,

biotechnology companies require significant amounts of capital in order to develop their

clinical programs. The capital-raising environment is always changing and there is risk that

necessary capital to complete development may not be readily available.

Risks To The Price Target

Sagimet's pipeline consists of FASN inhibitors denifanstat and TVB-3567, and the company’s

valuation will depend on the ability of these candidates to continually advance. Should

the clinical trials of these candidates fail, should competitive programs generate more

compelling results, or should Sagimet not be able to secure sufficient funding to advance their